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Exome-first approach identified a novel gloss deletion
associated with Lowe syndrome
Miki Watanabe1,4, Ryuji Nakagawa2,4, Tomohiro Kohmoto1,4, Takuya Naruto1, Ken-ichi Suga2, Aya Goji2, Hideaki Horikawa1,3,
Kiyoshi Masuda1, Shoji Kagami2 and Issei Imoto1,3
Lowe syndrome (LS) is an X-linked disorder affecting the eyes, nervous system and kidneys, typically caused by missense or
nonsense/frameshift OCRL mutations. We report a 6-month-old male clinically suspected to have LS, but without the Fanconi-type
renal dysfunction. Using a targeted-exome sequencing-first approach, LS was diagnosed by the identification of a deletion
involving 1.7 Mb at Xq25-q26.1, encompassing the entire OCRL gene and neighboring loci.
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Lowe syndrome (LS, the oculocerebrorenal syndrome of Lowe,
OCRL; OMIM #309000) is a rare, X-linked disorder characterized by
the diagnostic triad of congenital cataracts, cognitive and
behavioral impairment and renal proximal tubulopathy in almost
all affected males, with an estimated prevalence of 1 in 500,000 in
the general population.1–3 At birth, ocular involvement with
bilateral cataracts and severe hypotonia were usually present, but
these findings may also manifest in unrelated disorders, including
congenital infections, peroxisomal disorders, mitochondriopathies,
congenital myotonic dystrophies or congenital myopathies.1
Varying degrees of renal involvement (proximal renal tubular
dysfunction of the Fanconi type) may not be clinically apparent in
the first few months of life, making differential diagnosis to
exclude alternative disorders difficult.1
LS is caused by mutations involving OCRL (OMIM #300535),
which encodes a member of the inositol-5-phosphatase protein
family, OCRL1. OCRL locates to Xq25-q26.1 (hg19), and contains 24
exons, 23 of which are for protein coding.4 LS is typically
attributed to OCRL protein-truncating nonsense/frameshift
mutations or, less frequently, missense mutations involving the
catalytic domain. Approximately 6% of LS cases result from exonic
deletions, predominantly involving the 5′ region of OCRL.5,6
Deletion of the entire OCRL gene has also been previously
described in four affected males: some of these large-scale
deletion events were associated with more profound clinical
features.6–9 Among them, only one case with an ~ 4 Mb deletion
encompassing OCRL and several flanking genes were reported in
affected males with severe features of LS.9
Recently, next-generation sequencing (NGS), particularly whole-
exome sequencing (WES) or targeted-exome sequencing (TES),
have been adopted in clinical testing for patients with
undiagnosed congenital diseases suspected to be genetic in
origin. Single-nucleotide variations (SNVs) and small insertions/
deletions (indels), as well as gross copy-number variations (CNVs)
involved in a defect of disease-causing genes can be detected
using WES/TES simultaneously.10 Here, we report a second case of
LS caused by a large deletion encompassing the entire OCRL
gene and nearby loci, successfully detected by a TES-first
approach using a disease-related exome panel with subsequent
chromosomal microarray (CMA)-based fine mapping.11
A 6-month-old male infant was the first child born to healthy,
non-consanguineous Japanese parents with an unremarkable
family history. After an uneventful pregnancy, he was delivered at
38 weeks and 5 days of gestation by Cesarean section at a local
hospital. He had a birth weight of 2,100 g (−2.5 s.d.), a length of
44.5 cm (−2.0 s.d.) and a head circumference of 32 cm (−0.9 s.d.).
Generalized hypotonia, right cryptorchidism and inguinal hernia
were noted at birth. At the age of 13 days, mild corneal opacities
were observed bilaterally. Because of these symptoms and being
underdeveloped for his gestational age, congenital disease was
suspected and the infant transferred to our hospital at age
49 days: when he weighed 3,530 g (−2.3 s.d.) and was 51.5 cm
(−2.3 s.d.) in length. Cranial ultrasound was unremarkable.
His clinical course was characterized by developmental delay,
short stature, generalized hypotonia, and bilateral mild corneal
opacity and congenital cataracts. Early remedial surgery was
recommended after ophthalmologic examination to prevent
form-deprivation amblyopia. Blood investigation revealed ele-
vated alkaline phosphatase (2,187 IU/l), whereas other laboratory
tests, including assays for various metabolic disorders, were
unremarkable. Conventional chromosome G-banding analysis
presented a normal 46,XY karyotype. At age 79 days, lensectomy
was performed. At the age of 4 months, horizontal nystagmus was
conspicuous. Cranial ultrasound showed obscure corpus callosum,
and enlarged bilateral lateral ventricles and subarachnoid space.
By 6 months, he weighed 5,580 g (−2.7 s.d.) and was 60.9 cm
(−2.9 s.d.) in length. He lacked head control. Blood and urine tests
were essentially normal. The patient was suspected to have LS
because of his bilateral dense congenital cataracts, infantile
congenital hypotonia, delayed development, short stature and
mild ventriculomegaly,1–3 although no signs of renal tubular
dysfunction were observed.
1Department of Human Genetics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; 2Department of Paediatrics, Graduate School of Biomedical
Sciences, Tokushima University, Tokushima, Japan and 3Support Center for Advanced Medical Sciences, Graduate School of Biomedical Sciences, Tokushima University,
Tokushima, Japan.
Correspondence: I Imoto (issehgen@tokushima-u.ac.jp)
4These authors contributed equally to this work.
Received 3 September 2016; revised 16 September 2016; accepted 19 September 2016
Citation: Human Genome Variation (2016) 3, 16037; doi:10.1038/hgv.2016.37
Official journal of the Japan Society of Human Genetics
www.nature.com/hgv
Molecular genetic analysis was performed on genomic DNA
extracted from a blood sample after informed consent was
obtained from the parents. The study was approved by the Ethics
Committee at Tokushima University. We performed TES using a
TruSight One Sequencing Panel (Illumina, San Diego, CA, USA) and
a MiSeq (Illumina) with our pipeline for NGS data analysis, as
described previously.11,12 The detection of CNVs using TES data
with a resolution of a single exon to several exons, depending on
exon sizes, was performed as described previously.10,11 These
analyses revealed no disease-causing SNVs or indels, but did
detect a deletion of all exons of the OCRL gene between positions
128,674,407 and 128,724,257 of chromosome X (Xq25-q26.1,
hg19), indicating the complete loss of at least the entire OCRL
gene (Figure 1a). Validation and fine mapping of the deleted
region were performed by CMA using an Affymetrix CytoScan HD
chromosome microarray platform (Affymetrix, Santa Clara, CA,
USA), as described previously.10,11 CMA detected a complete
chromosomal deletion within Xq25–q26.1 as 46,XY.arr[hg19]
Xq25q26.1(127,201,958–128,877,282) × 0 (Figure 1b). In addition
to the entire OCRL gene, the deleted region comprises two genes,
SMARCA1 (OMIM #300012) encoding a member of the SWI/SNF
family of proteins involved in chromatin remodeling and APLN
Figure 1. (a) An eXome-Hidden Markov Model v1.0 (XHMM, https://atgu.mgh.harvard.edu/xhmm/) analysis using TES data detected genomic
copy-number loss of the entire OCRL gene (24 target exons) located within Xq25-q26.1, suggesting an ~ 50 kb deletion (red horizontal bar).
The x axis denotes the physical position and the y axis indicates the Z-score of principal component analysis (PCA)-normalized read depth.
Purple circles connected by red lines show values for the individual subjected to TES in this study. Gray dots with gray connected lines
represent the results of normalized read depth obtained from in-house control data (N= 126). (b) CMA using an Affymetrix Cytoscan HD array
demonstrated a 1.7 Mb deletion within Xq25-q26.1 (red horizontal line). Weighted copy-number log2 ratio, genes and segmental duplications
around the deleted region are shown. Arrows indicate direction of transcription. Dashed lines indicate deletion break points. Among the four
genes involved in deleted region, OCRL is the only locus included in the TruSight One sequencing panel for TES. Compared with TES-based
CNV detection, distal and proximal break points of the deleted region were shifted to distal and proximal sides, respectively, in CMA analysis
because of lacking target exons other than those of OCRL within the deleted region. CMA, chromosomal microarray; CNV, copy-number
variation; OCRL, oculocerebrorenal syndrome of Lowe; TES, targeted-exome sequencing.
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(OMIM #300297) specifying an endogenous ligand for the G
protein-coupled apelin receptor, and the 5′ region of XPNPEP2
(OMIM #300145) encoding aminopeptidase P (Figure 1b). Apelin is
a neuropeptide expressed in the supraoptic and paraventricular
nuclei.13 The patient presented no additional clinical symptoms or
dysmorphic features besides LS consequent on deletion of these
OCRL-flanking loci.9 This deletion is not present in the Human
Gene Mutation Database professional 2016.2 (HGMD, http://www.
hgmd.org/) and ClinVar (http://www.ncbi.nml.nih.org/clinvar/),
suggesting it to be novel. This deletion was not confirmed as
de novo because of the unavailability of his mother’s DNA.
LS should be suspected in infant males presenting with
congenital cataracts, severe hypotonia and renal tubular dysfunc-
tion of the Fanconi type during early postnatal life.1–3 Early
diagnosis and treatment of metabolic disturbances may reduce
the morbidity and mortality implicated in this syndrome.14 For the
diagnosis of LS, defects involving ocular, central nervous and renal
systems are requisite.1 In early infancy, it may be difficult to
exclude alternative diagnoses because of a frequent lack of renal
Fanconi-type syndrome, as in the present case.1 Therefore,
multiple genes possibly responsible for clinical manifestations,
including OCRL, should be evaluated for the differential diagnosis
of LS in some cases. In addition, genetic variations such as
SNV/indels, gross insertion/deletion and translocations may
underlie disease-causing gene defects. Considering that TES can
simultaneously detect both exonic SNVs/indels and CNVs in
multiple disease-causing genes in a diagnostic setting for human
genetic diseases,10,11 this TES-first approach can facilitate differ-
ential diagnosis of LS for patients lacking distinctive manifesta-
tions/symptoms, as observed in the present case, in a cost- and
time-effective manner.
Previously, Addis et al.9 have reported a male patient with an
~ 4 Mb microdeletion encompassing OCRL and flanking genes,
such as DCAF12L1 (WDR40B), PRR32, ACTRT1 and SMARCA1, who
was diagnosed with LS at birth on the basis of typical
oculocerebrorenal manifestations and renal Fanconi disease
(Figure 2). As in the present case, no additional clinical symptoms
or dysmorphic features besides LS consequent on deletion of
these flanking genes were presented until his death from
unknown causes at 5 months of age, although only SMARCA1 is
the commonly deleted flanking gene between the two cases.9
On the basis of the phenotypes observed in two cases, therefore,
it remained unclear whether patients with LS caused by gloss
deletions present additional features besides LS that are able to be
explained by OCRL-flanking genes involved in the deleted regions.
A small number of cases with LS caused by microdeletions
containing OCRL and a few nearby genes suggest that larger
deletions around OCRL in males might be lethal (Figure 2).
HGV DATABASE
The relevant data from this Data Report are hosted at the Human
Genome Variation Database at http://dx.doi.org/10.6084/m9.
figshare.hgv.897.
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